These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23723377)

  • 1. Editorial: A missing link? Monocyte activation by uremic toxins in cardiorenal syndrome.
    Armstrong EJ; Granick JL; Simon SI
    J Leukoc Biol; 2013 Jun; 93(6):821-3. PubMed ID: 23723377
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease.
    Ito S; Higuchi Y; Yagi Y; Nishijima F; Yamato H; Ishii H; Osaka M; Yoshida M
    J Leukoc Biol; 2013 Jun; 93(6):837-45. PubMed ID: 23362306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoxyl Sulfate Contributes to Adipose Tissue Inflammation through the Activation of NADPH Oxidase.
    Tanaka S; Watanabe H; Nakano T; Imafuku T; Kato H; Tokumaru K; Arimura N; Enoki Y; Maeda H; Tanaka M; Matsushita K; Fukagawa M; Maruyama T
    Toxins (Basel); 2020 Aug; 12(8):. PubMed ID: 32764271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
    Kamiński TW; Pawlak K; Karbowska M; Myśliwiec M; Pawlak D
    BMC Nephrol; 2017 Jan; 18(1):35. PubMed ID: 28122514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uremic toxins and oral adsorbents.
    Goto S; Yoshiya K; Kita T; Fujii H; Fukagawa M
    Ther Apher Dial; 2011 Apr; 15(2):132-4. PubMed ID: 21426503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiorenal syndrome: role of protein-bound uremic toxins.
    Lekawanvijit S; Krum H
    J Ren Nutr; 2015 Mar; 25(2):149-54. PubMed ID: 25556308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aryl Hydrocarbon Receptor Activation in Chronic Kidney Disease: Role of Uremic Toxins.
    Brito JS; Borges NA; Esgalhado M; Magliano DC; Soulage CO; Mafra D
    Nephron; 2017; 137(1):1-7. PubMed ID: 28490014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
    Yamaguchi J; Tanaka T; Inagi R
    Nephron; 2017; 135(3):201-206. PubMed ID: 27960172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins.
    Lekawanvijit S; Kompa AR; Wang BH; Kelly DJ; Krum H
    Circ Res; 2012 Nov; 111(11):1470-83. PubMed ID: 23139286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ROS and oxidative stress in CKD patients: is it the mitochondria that keeps CKD patients in bed?
    Hagmann H; Brinkkoetter PT
    Nephrol Dial Transplant; 2015 Jun; 30(6):867-8. PubMed ID: 25735768
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease.
    Fujii H; Nakai K; Fukagawa M
    Ther Apher Dial; 2011 Apr; 15(2):125-8. PubMed ID: 21426501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AST-120 ameliorates lowered exercise capacity and mitochondrial biogenesis in the skeletal muscle from mice with chronic kidney disease via reducing oxidative stress.
    Nishikawa M; Ishimori N; Takada S; Saito A; Kadoguchi T; Furihata T; Fukushima A; Matsushima S; Yokota T; Kinugawa S; Tsutsui H
    Nephrol Dial Transplant; 2015 Jun; 30(6):934-42. PubMed ID: 25878055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120.
    Niwa T
    Ther Apher Dial; 2011 Apr; 15(2):120-4. PubMed ID: 21426500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of indoxyl sulfate in renal and central nervous system toxicities during cisplatin-induced acute renal failure.
    Iwata K; Watanabe H; Morisaki T; Matsuzaki T; Ohmura T; Hamada A; Saito H
    Pharm Res; 2007 Apr; 24(4):662-71. PubMed ID: 17318420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oral adsorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats.
    Aoyama I; Shimokata K; Niwa T
    Nephron; 2002; 92(3):635-51. PubMed ID: 12372949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease.
    Hung SC; Kuo KL; Wu CC; Tarng DC
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28174171
    [No Abstract]   [Full Text] [Related]  

  • 17. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease.
    Rossi M; Campbell KL; Johnson DW; Stanton T; Vesey DA; Coombes JS; Weston KS; Hawley CM; McWhinney BC; Ungerer JP; Isbel N
    Arch Med Res; 2014 May; 45(4):309-17. PubMed ID: 24751327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring binding characteristics and the related competition of different protein-bound uremic toxins.
    Deltombe O; de Loor H; Glorieux G; Dhondt A; Van Biesen W; Meijers B; Eloot S
    Biochimie; 2017 Aug; 139():20-26. PubMed ID: 28528271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting protein-bound uremic toxins in chronic kidney disease.
    Niwa T
    Expert Opin Ther Targets; 2013 Nov; 17(11):1287-301. PubMed ID: 23941498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.